REGN
Regeneron Pharmaceuticals Inc
NASDAQ: REGN · HEALTHCARE · BIOTECHNOLOGY
$707.06
+3.02% today
Updated 2026-04-30
Market cap
$74.13B
P/E ratio
17.27
P/S ratio
4.97x
EPS (TTM)
$40.94
Dividend yield
0.52%
52W range
$475 – $820
Volume
0.7M
WallStSmart proprietary scores
64
out of 100
Grade: C+
Hold
Investment rating
5.3
Growth
C+7.3
Quality
B+7.5
Profitability
B+8.0
Valuation
A3/9
Piotroski F-Score
Weak
4.7
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$877.73
+24.14%
12-Month target
$741.53
+4.88%
Intrinsic (DCF)
$1,464.40
Margin of safety
+51.72%
4 Strong Buy18 Buy7 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Altman Z 4.68 — safe zone
+ Profit margin 29.60% — above average
+ Free cash flow $922.00M — positive
+ Revenue growth 19.00% QoQ
+ 51.72% below intrinsic value
Risks
- Piotroski 3/9 — weak financial health
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $12.17B | $13.12B | $14.20B | $14.34B | $14.92B | $16.1B |
| Net income | $4.34B | $3.95B | $4.41B | $4.50B | $844.60M | — |
| EPS | — | — | — | — | $40.94 | $46.75 |
| Free cash flow | $4.42B | $3.67B | $3.66B | $4.08B | $922.00M | — |
| Profit margin | 35.64% | 30.14% | 31.07% | 31.41% | 29.60% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-01 | RYAN, ARTHUR F | Sale | 40 | $779.71 |
| 2026-04-01 | RYAN, ARTHUR F | Sale | 14 | $775.58 |
| 2026-04-01 | RYAN, ARTHUR F | Sale | 13 | $776.62 |
Peer comparison
Smart narrative
Regeneron Pharmaceuticals Inc trades at $707.06. representing a P/E of 17.27x trailing earnings. Our Smart Value Score of 64/100 indicates the stock is good. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 4.68, it sits in the safe zone. TTM revenue stands at $14.92B. with profit margins at 29.60%. Our DCF model estimates intrinsic value at $1,464.40.
Frequently asked questions
What is Regeneron Pharmaceuticals Inc's stock price?
Regeneron Pharmaceuticals Inc (REGN) trades at $707.06.
Is Regeneron Pharmaceuticals Inc overvalued?
Smart Value Score 64/100 (Grade C+, Hold). DCF value $1,464.40.
What is the price target of Regeneron Pharmaceuticals Inc (REGN)?
The analyst target price is $877.73, representing +24.1% upside from the current price of $707.06.
What is the intrinsic value of Regeneron Pharmaceuticals Inc (REGN)?
Based on our DCF model, intrinsic value is $1,464.40, a +51.7% margin of safety versus $707.06.
What is the future stock price of REGN by 2030?
Our research-backed model estimates Regeneron Pharmaceuticals Inc could reach $2,518.03 by 2030, based on analyst consensus, management guidance, and sector analysis.
What is Regeneron Pharmaceuticals Inc's revenue?
TTM revenue is $14.92B.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
4.68 — safe zone.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio4.97x
ROE14.50%
Beta0.40
50D MA$757.21
200D MA$682.87
Shares out0.10B
Float0.10B
Short ratio—
Avg volume0.7M
Performance
1 week-10.40%
1 month-11.17%
3 months-8.42%
YTD-11.08%
1 year—
3 years—
5 years—